Treats cerebral folate transport deficiency. ANDA 71198, held by Barr. Leucovorin Calcium.
As of Nov 16, 2026, ANDA 71198 (Leucovorin Calcium), held by Barr, was first approved by FDA on Sep 24, 1987, with 29 approved supplements and 0 published complete response letters.
Leucovorin calcium tablets are a folate analog indicated: To reduce the toxicity of: Methotrexate in adult patients with impaired methotrexate elimination, and Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult patients. For the treatment of cerebral folate transport deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). Limitations of Use Leucovorin calcium tablets are not recommended for use in patients with a deficiency of methenyltetrahydrofolate synthetase (MTHFS) because MTHFS is a primary enzyme in the metabolism of leucovorin to 5-methenyltetrahydrofolate.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 24, 1987 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Leucovorin CalciumEQ 5MG BASE · tablet;oral | Leucovorin Calcium | Rx |
| May 5, 2026 | Supplement 43Labeling · Standard review | Approved | None posted |
| Dec 26, 2000 | Supplement 30Manufacturing | Approved | None posted |
| Apr 21, 2000 | Supplement 29Manufacturing | Approved | None posted |
| Apr 21, 2000 | Supplement 28Manufacturing | Approved | None posted |
| Dec 21, 1999 | Supplement 27Manufacturing | Approved | None posted |
| Sep 16, 1999 | Supplement 26Manufacturing | Approved | None posted |
| May 20, 1999 | Supplement 25Manufacturing | Approved | None posted |
| Dec 1, 1998 | Supplement 24Manufacturing | Approved | None posted |
| Jul 24, 1998 | Supplement 23Manufacturing | Approved | None posted |
| Nov 10, 1997 | Supplement 22Labeling | Approved | None posted |
| Jun 20, 1997 | Supplement 21Manufacturing | Approved | None posted |
| Jun 20, 1997 | Supplement 20Manufacturing | Approved | None posted |
| Apr 7, 1997 | Supplement 19Manufacturing | Approved | None posted |
| Feb 10, 1995 | Supplement 18Manufacturing | Approved | None posted |
| Dec 23, 1994 | Supplement 17Manufacturing | Approved | None posted |
| Oct 11, 1994 | Supplement 16Manufacturing | Approved | None posted |
| Jul 16, 1992 | Supplement 15Labeling | Approved | None posted |
| Apr 3, 1992 | Supplement 14Manufacturing | Approved | None posted |
| Apr 3, 1992 | Supplement 12Manufacturing | Approved | None posted |
| Feb 23, 1991 | Supplement 10Labeling | Approved | None posted |
| Feb 23, 1991 | Supplement 9Manufacturing | Approved | None posted |
| Feb 23, 1991 | Supplement 8Manufacturing | Approved | None posted |
| Feb 23, 1991 | Supplement 7Labeling | Approved | None posted |
| Feb 23, 1991 | Supplement 6Manufacturing | Approved | None posted |
| Dec 18, 1990 | Supplement 11Labeling | Approved | None posted |
| Mar 20, 1989 | Supplement 5Manufacturing | Approved | None posted |
| Mar 20, 1989 | Supplement 4Labeling | Approved | None posted |
| Mar 20, 1989 | Supplement 3Manufacturing | Approved | None posted |
| Mar 20, 1989 | Supplement 2Manufacturing | Approved | None posted |
| Sep 24, 1987 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters